Key Takeaways
- Gross margin surged on mix, not pricing: Standalone material cost ratio fell to 27.62% in Q3 as high-margin ROW and chronic sales jumped while low-margin acute therapies stalled, a one-time composition effect that management expects to normalize.
- Unichem turnaround is real and margin-accretive: Unichem EBITDA margin nearly doubled to ~12% from ~5% a year ago, driven by operational efficiencies and cost synergies, with management saying there is "a long way to go."
- Generic exports are a drag with moving parts: South Africa tender losses wiped out ~INR75-80 crores annually, Australia supply issues are now resolved, and the U.K. is fiercely competitive, but management guided 15-17% U.K. growth next year on price recovery and launches.
- Full-year margin guidance raised materially: Standalone EBITDA now seen at 23-24% (vs ~21% originally) and consolidated at 19.18-19.5% (vs ~18%), with further 100-150 bps improvement targeted over the next 3-4 years.
- What to watch next quarter: Whether the Q3 gross margin spike reverses as guided, FY26 EBITDA guidance due with Q4 results, and any update on U.S. business ramp-up through Unichem.
Margin Drivers: The Mix Effect
- Product mix, not input prices, drove the quarter: Turnover grew ~10% while material cost fell ~5%, but management explicitly stated there was no reduction in material pricing. The shift came from a surge in high-margin ROW business (up ~50% from a very low base last year) and chronic therapies outperforming, while low-margin antimalarials, antibacterials, and cough-and-cold barely grew.
- ROW base effect is one-time: ROW market business was only ~INR104 crores in Q3 last year and grew almost 50% this year. Management flagged that the branded formulations growth number is a one-time impact from last year's abnormally low shipments, with normalized growth at plus/minus 5-7%.
- Material cost ratio trend confirms the shift: Standalone material cost ratio improved sequentially from 29.59% in Q2 to 27.62% in Q3, and the 9-month figure of 28.73% compares to 32% last year, an improvement of ~3.37 percentage points. For Q4, management expects the ratio to stay broadly around 28-29%.
- Domestic margin is structurally higher: While management declined to quantify the domestic business EBITDA margin, they confirmed it is "definitely higher" than the standalone 23-24% and will further improve as recently added field force becomes productive, a process that takes ~3 years in normal therapies.
- Productivity gains are compounding: Permanent employee productivity is up by ~20,000 on average, and management expects ~INR25,000 to ~INR30,000 average productivity improvements to continue annually even with 300-400 people additions per year.
A.K. Jain: "See, gross margin this particular quarter was exceptionally high mainly because the overall, let's say, turnover in this quarter has grown by around 10%. Material cost, there is a significant reduction, against 10% growth, material cost has come down by around 5%. So that is the impact."
Unichem Turnaround
- EBITDA margin nearly doubled year-on-year: Unichem's margin improved from around 5% last year to close to 12%, driven by operational efficiencies, synergetic benefits from the Ipca integration, and buying efficiencies. The Goa facility, newly commissioned, is gradually ramping up production and lowering operating costs.
- Cost structure is being stripped down: Bayshore's administrative cost burden has been removed because Unichem already has the people and does not need to hire additional ones for Bayshore and Ipca business, resulting in an overall operational cost decrease.
- Ipca portfolio cross-sell is still early: Only around 4 products have been shipped into Unichem's distribution so far, with 7-8 more in the pipeline. Stocks went in during the current quarter and end of last quarter, but nothing meaningful has yet shown up in consolidated numbers.
- U.S. business is being rebuilt through Unichem: Previous marketing partners for U.S. business have been replaced with Unichem, with a profit-and-cost-sharing formula in place. The Unichem team has started bidding for products with cost competency and is gaining orders slowly, but there is a gestation period from goods receipt to sales commencement.
- No merger planned, by design: Management cited a hedging strategy for keeping Ipca and Unichem as separate listed entities, referencing past regulatory setbacks: "if anything happens to Ipca or anything happens to Unichem like we have burned our fingers in past, so we don't want that situation to have."
A.K. Jain: "And overall, it's basically improvement in operation that has got the results right now and a long way to go, I would say that, the margin will keep on improving as far as Unichem is concerned."
Generic Exports: Headwinds and Recoveries
- South Africa tender loss is the biggest hole: The business dropped from ~INR120 crores annually to ~INR40 crores, a decline of ~INR75-80 crores from lost tender orders. No recovery timeline was offered.
- Australia supply issues are resolved: Australia and New Zealand numbers had been down due to supply chain issues on ACI used for formulations. Those issues are now resolved, Australia numbers improved in Q3, and further improvement is expected next quarter.
- U.K. is fiercely competitive but turning: U.K. numbers are flat versus the previous year's 9-month period, but prices started improving from Q3 onwards and a lot of launches are in the pipeline. Management guided around 15-17% overall U.K. growth in the next financial year.
- Europe remains a steady grower: Management expects Europe to continue growing at double-digit rates.
- API business is stabilizing at modest growth: The COVID-era chloroquine and hydroxychloroquine windfall is gone, and Iran business (~INR75-80 crores) is now zero because of currency unavailability. Sartans, the largest API product segment, are seeing volume growth but muted sales value. Management expects 8-10% API growth going forward with a neutral pricing outlook and no further price improvements in the next two quarters.
A.K. Jain: "Let's say, I think second quarter was very bad. But third quarter onwards, the prices have again started improving there and business has started improving overall. And I think we have a lot of launches also in pipeline. So I think in U.K. numbers, we will see around 15% to 17% kind of overall growth in next financial year."
Domestic Formulations: Chronic Strength, Acute Stagnation
- Pain management is the engine: The pain portfolio grew 14%, led by osteoarthritis and rheumatoid arthritis. Zerodol is growing at ~1.5x the market, and management sees no problem in sustaining 13-14% growth for the next 3-4 years.
- Rheumatology has a long runway: The portfolio has grown at 1.5x market growth for 10-15 years, and management does not foresee that growth rate coming down in the next 5 years, citing significant work still to be done to make therapies available across the country. New product portfolios will be added as patent expiries occur.
- Acute therapies dragged overall growth: Antimalarials had zero growth, antibacterials grew only 1%, and cough-and-cold grew only 4%. This mix shift, while negative for topline, was positive for margins since these are the lowest-margin categories.
- New therapy divisions are being built: A new orthopedics/dentals division has been started with ~150 people added so far and another ~200 planned; it should reach breakeven next year. A new cardiology division with ~300 people will be added next financial year. The company is also working on cosmetic dermatology, an area it currently misses.
- Domestic growth target is 1.5x IPM: Management expects to continue growing at 1.5x the Indian pharmaceutical market growth rate in the coming few years. Promotional market business is looking at around 8-9% growth for the full financial year.
A.K. Jain: "Rheumatology portfolio, is last 10, 15 years, also, we have seen continuously it's growing 1.5x the market growth. And we don't foresee next 5 years also that growth rate can come down."
Subsidiaries & Capacity
- Most subsidiaries are now profitable: Except Pisgah and the associate company Krebs, all other subsidiaries are profitable. Bayshore's administrative cost burden has been removed from the books. Pisgah is expected to turn around in a couple of quarters.
- Dewas capacity is online but underutilized: The Dewas facility has started with capacity utilization at around 35-40%. A lot of regulatory approvals and inspections are pending; once those happen, utilization will pick up.
- Unichem has adequate formulation capacity: Management stated that for the next 4-5 years, no further capacity is needed at Unichem other than routine improvements. API bottlenecks at Pithampur are being addressed.
- U.S. product shipments have resumed: Ipca has manufactured and shipped 4 of the ~10 products that were previously sold in the U.S. market before the FDA issue, with a few other products on the verge of being manufactured.
- ANDA filing pace is set: Ipca expects to file 5-6 ANDAs every year, and Unichem will continue a similar number. The strategy is to use captive API. Combined R&D spend is currently ~3-3.25% and likely to move to ~4%.
Harish Kamath: "Except Pisgah and our associate company Krebs, other all companies are profitable as on date... So only Pisgah and Krebs are little cause of concern."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Standalone EBITDA margin | 23% to 24% (raised from ~21%) | FY25 full year |
| Consolidated EBITDA margin | 19.18% to 19.5% (raised from ~18%) | FY25 full year |
| Q4 material cost ratio | Broadly around 28% to 29% | Q4 FY25 |
| U.K. business growth | 15% to 17% overall growth | FY26 |
| API business growth | 8% to 10% | Going forward |
| Promotional market business growth | 8% to 9% | FY25 full year |
| Net debt (standalone) | Practically nil | FY26 |
| Margin improvement | 100 to 150 bps | Next 3-4 years |
| R&D spend | Move to ~4% of revenue | No date; directional |
| Domestic growth vs IPM | 1.5x IPM growth | Coming few years |
| Pisgah turnaround | Profitable | Couple of quarters |
| New orthopedics/dentals division | Breakeven | FY26 |
| New cardiology division | Launch with ~300 people | FY26 |
| ANDA filings (Ipca) | 5-6 per year | Ongoing annually |
| Effective tax rate | 27% to 28% | Ongoing |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Standalone revenue growth | ~10% YoY |
| Domestic formulation growth | ~13% for the quarter |
| API business growth | ~12% for the quarter |
| Overall formulation business growth | ~6% for the quarter |
| Standalone EBITDA margin | ~24.25%, vs 18.52% in Q3 FY24, improvement of ~5.73 ppt |
| Standalone 9M EBITDA margin | ~23.14%, vs 19.55% in 9M FY24, improvement of ~3.59 ppt |
| Consolidated EBITDA margin | ~19.87%, vs 16.1% in Q3 FY24, improvement of ~3.77 ppt |
| Consolidated 9M EBITDA margin | ~19.18%, vs 17.34% in 9M FY24, improvement of ~1.84 ppt |
| Full-year standalone EBITDA margin guidance | ~23% to 24% (original guidance ~21%) |
| Full-year consolidated EBITDA margin guidance | ~19.18% to 19.5% (original guidance ~18%) |
| Standalone material cost ratio | ~27.62% in Q3, vs ~28.9% in Q1 and ~29.59% in Q2 |
| 9M material cost ratio | 28.73%, vs ~32% in 9M FY24, improvement of ~3.37 ppt |
| Unichem EBITDA margin | ~12%, vs ~5% in Q3 FY24 |
| Domestic market share (MAT Dec '24) | 2.05%, up 11 bps from 1.95% at Dec '23 |
| IQVIA-tracked domestic growth | 11.4%, vs IPM growth of ~7.4% |
| Chronic segment growth (IQVIA) | ~17.1%, vs IPM chronic growth of ~9.7% |
| Acute segment growth (IQVIA) | 8.7%, vs IPM acute growth of ~6% |
| Pain portfolio growth (9M FY25) | ~14% |
| Domestic portfolio internal growth (9M FY25) | ~12% |
| ROW market business growth | ~50% YoY, from ~₹104 cr in Q3 FY24 |
| EU generics growth | ~14% to 15% |
| U.K. generics growth outlook (FY26) | ~15% to 17% |
| API business growth outlook | 8% to 10% |
| Promotional market business growth outlook (FY25) | ~8% to 9% |
| MR productivity per month (9M FY25) | ₹4,45,000, vs ~₹4,25,000 with 6,300 people in 9M FY24 |
| MR count | ~6,700 |
| Dewas capacity utilization | ~35% to 40% |
| Ipca standalone gross debt | ~₹900 cr |
| Ipca standalone cash | ~₹600 cr |
| Ipca standalone net debt | ~₹300 cr |
| Effective tax rate | ~27% to 28% |
| R&D spend (Ipca + Unichem combined) | ~3% to 3.25% of sales, likely to move to ~4% |
| Pain management share of domestic business | ~52% |
| South Africa business decline | ~₹75 cr to ₹80 cr decline in FY25 from ~₹120 cr annual run-rate |
| Iran business | ₹0, down from ~₹75 cr to ₹80 cr annually |